Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2026-526299-21-00
Authorised, recruiting Phase I

An Open-Label Study of IDE034 in Adult Participants with Locally Advanced/Metastatic Solid Tumors

2026-526299-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Ideaya Biosciences Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Female Urogenital Diseases and Pregnancy Complications
Decision date
28/08/2026
Enrollment target
15
Sites
Spain

Condition studied

Locally Advanced/Metastatic Solid Tumors -non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), endometrial cancer, high-grade serous ovarian cancer (HGSOC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), and castration-resistant prostate cancer (CRPC)

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526299-21-00 on CTIS ↗ ← All trials in the EU